

16 November 2009

Company Announcements Office ASX Limited Exchange Centre 20 Bridge Street SYDNEY NSW 2000

Dear Sir / Madam

## QRxPharma Limited ACN 102 254 151 (ASX code: QRx) Notification under section 708AA(2)(f) of the Corporations Act 2001 (Cth)

QRXPharma has announced a renounceable rights issue (**Rights Issue**) and placement (**Placement**). Details of the Rights Issue and Placement are set out in the announcement of today's date.

QRxPharma gives notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) as modified by ASIC Class Order CO 08/35 (Corporations Act) that:

- 1. QRxPharma will offer ordinary shares in QRxPharma for issue pursuant to the Rights Issue and the Placement without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2. As at the date of this notice:
  - (a) QRxPharma has complied with the provisions of Chapter 2M of the Corporations Act as they apply to QRxPharma;
  - (b) QRxPharma has complied with section 674 of the Corporations Act; and
  - (c) there is no "excluded information" within the meaning of sections 708AA(8) and 708AA(9) of the Corporations Act which is required to be disclosed under section 708AA(7)(d) of the Corporations Act.
- 3. The potential effect that the Rights Issue and the Placement will have on the control of QRxPharma, and the consequences of that effect, will depend upon a number of factors, including investor demand. Based on the fact that no QRxPharma shareholder has voting power exceeding 20% of QRxPharma's issued shares, QRxPharma does not expect the Rights Issue or the Placement to give rise to any material effect on the control of QRxPharma other than as set out above.

Yours faithfully QRxPharma Limited

Chris Campbell
Company Secretary

C. J. Campbell